Arbitration and Conciliation Act, 1996 - provisions of Section 8 of Commercial Courts Act, 2015, bar filing of a revision petition against interlocutory order of Commercial Court, except in exceptional circumstances: HC (See 'Legal Desk') SEBI - Public company cannot bypass public offer rules even under guise of private placements if more than 50 persons are involved: SEBI (See 'Legal Desk') DoP Signs MoU with Department of Agriculture to strengthen PAN-India Sample Logistics (See 'Corp Brief') IBC - Deed of undertaking is not guarantee, and resolution plan does not extinguish rights against third-party security providers unless debt is fully satisfied: SC (See 'Legal Desk') Program launched to train 1 Million young people in AI Skills (See 'Corp Brief') PMLA - Continued incarceration of under-trial, without commencement or reasonable progress of trial, results in pre-trial detention being converted into punishment, which is impermissible in law: SC (See 'Legal Desk') ECI to host International Conference on Democracy and Election Management (See 'Corp Brief') SEBI - Inadvertence or technical issues do not absolve listed company from its statutory disclosure obligations: SEBI (See 'Legal Desk') A&C - Enforcement of foreign award can be refused if it is contrary to public policy, however, mere contravention of law does not equate to violation of public policy: HC (See 'Legal Desk') Indusfood Manufacturing 2026 & FoodTech 4.0 Opens at Yashobhoomi (See 'Corp Brief') CCI approves acquisition of Krosaki Harima Corporation by Nippon Steel (See 'Corp Brief') A&C - Right to object to appointment of ineligible arbitrator cannot be taken away by mere implication: SC (See 'Legal Desk') CCI okays acquisition of additional shareholding in Roppen Transportation by MIH Investments (See 'Corp Brief') Ministry of I&B's WaveX signs MoU with FITT-IIT Delhi to boost Innovation (See 'Corp Brief') A&C - Conferment of jurisdiction on specific court or creation of public forum, though eminently significant, may not be decisive test to answer and decide whether arbitrability is impliedly barred: SC (See 'Legal Desk') Working Group discusses Regional Language AI Infrastructure and Reimagining AI Education (See 'Corp Brief') Pax Comfort and Safety enhanced with better Stations: Railways (See 'Corp Brief') IPR - Gaay Chhap had shown prior and continuous use of its marks and made out strong prima facie case of trademark infringement and passing off: HC (See 'Legal Desk') IBBI Chairperson launches IICA PGIP program Website (See 'Corp Brief') Yadav reviews Action Plans of Rajasthan and Punjab to tackle Air Pollution (See 'Corp Brief') IPR - Even if trademark is accepted and advertised and, thereafter, no objection was filed against same, Sec 19 of Trade marks Act empowers Registrar to withdraw acceptance given to said Mark before its registration: HC (See 'Legal Desk') SAIL records Highest-Ever December Sales (See 'Corp Brief') Rajiv Ranjan Singh inaugurates Smart Green Aquaculture Farm (See 'Corp Brief') PMLA - It is not the case of the respondent that the petitioner at any point of time was an accused in the investigation or he was evading arrest - Essential requisites of s.73 of CrPC not met - Non-bailable warrants issued stand cancelled: HC (See 'Legal Desk') Railways utilises 80 Percent of CAPEX in First Three Quarters (See 'Corp Brief') Ships built by GSL & other yards are floating symbols of India's sovereignty: RM (See 'Corp Brief') Misc - A litigant cannot be placed in a situation where a statutory right of appeal is rendered illusory on account of procedural or administrative impediments: HC (See 'Legal Desk') Govt announces relaxation for Deep-Tech Startups for DSIR recognition (See 'Corp Brief') ICAR directed to set up laboratory for turmeric testing in Erode (See 'Corp Brief') SEBI - Levy of penalty shall commensurate to disproportionate gain or unfair advantage or loss caused to investor: SEBI (See 'Legal Desk') Fixed-Term Employment fixed under New Labour Codes (See CORP EINSICHT) Competition Law - When opposite party is not dominant in relevant market, question of abuse of dominant position u/s 4 of Competition Act does not arise: CCI (See 'Legal Desk') NTPC Western Region-I signs MoA with Gujarat Cancer & Research Institute (See 'Corp Brief') PMLA - COVID-19 limitation extension was intended to cover all proceedings, including those under PMLA: SAFEMA (See 'Legal Desk') Coal Output surges as Captive and Commercial Mines Perform Strongly (See 'Corp Brief') IBC - Non- stamping or insufficient stamping of one of documents relied upon by creditor does not impede initiation of insolvency resolution process, which differs from enforcement action: NCLT (See 'Legal Desk') National Textiles Ministers' Conference to be held in Guwahati (See 'Corp Brief') IBC - Penalty can be levied if lapses demonstrated non-compliance with statutory and regulatory obligations incumbent on IP, undermining interests of stakeholders and integrity of insolvency process: IBBI (See 'Legal Desk')

Print

Glenmark's Swiss arm gets nod to market Ryaltris nasal spray in Russia

Published: Feb 22, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 22, 2021: GLENMARK Pharmaceuticals on Monday said its Swiss subsidiary, Glenmark Specialty, has received marketing approval from Russian health regulators for its fixed-dose combination nasal spray, Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, like stuffy and runny nose, nasal itching, sneezing, as well as irritated eyes, in adults and children over 12 years of age.

"Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," said Csaba Kantor, Senior Vice President - Russia and CIS region, Glenmark.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent.

"Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country. We look forward to being able to make this innovative product available to patients in Russia as soon as possible," Mr Kantor added.

The company estimated that Ryaltris will be available to patients in Russia by the first quarter of 2021-22.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.